Heart failure with preserved ejection fraction (HFpEF) represents a multifaceted syndrome
related to complex pathologic mechanisms. Sacubitril/valsartan (Sac/val) has demonstrated …

Previous studies have confirmed the clinical efficacy of sacubitril/valsartan (Sac/Val) for the
treatment of heart failure with reduced ejection fraction (HFrEF). However, the role of Sac/Val …

The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown
to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF) …

Background/aims The persistent existence of pathological cardiac remodeling, resulting
from aortic stenosis, is related to poor clinical prognosis after successful transcatheter aortic …

Objectives: To investigate the effect and mechanism of sacubitril/valsartan on myocardial
fibrosis in rats following experimental myocardial infarction and in TGF-β1-treated …

Heart failure with preserved ejection fraction (HFpEF) is a morbid, fatal, and common
syndrome for which lack of evidence-based therapies. Salvianolic acid A (SAA), a major …

Background Heart failure (HF) is invariably accompanied by development of cardiac fibrosis,
a form of scarring that increases muscular tissue rigidity and decreases cardiac contractility …

Aims Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the
renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We …

Sažetak Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model
of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were administered with …

Background Sacubitril/valsartan has been demonstrated to promote left ventricular (LV)
reverse remodelling and improve outcomes in patients with heart failure (HF) with reduced …